SGLT2i与GLP-1RA相关包茎风险:丹麦队列研究
在丹麦开展基于人群的活性对照新用药者队列研究,模拟目标试验,纳入2016至2021年启动SGLT2i或GLP-1RA的成年男性二甲双胍使用者,采用逆概率治疗加权平衡混杂因素。SGLT2i组1年包茎风险为0.9%,GLP-1RA组为0.5%,1年风险比1.88(95%CI 1.43至2.47);8年累积风险分别为4.8%与3.6%,8年风险比1.36(95%CI 1.14至1.61)。
要点
- SGLT2i组1年包茎风险0.9%,GLP-1RA组0.5%,1年风险比1.88(95%CI 1.43至2.47)。
- 8年累积包茎风险SGLT2i组4.8%,GLP-1RA组3.6%,8年风险比1.36(95%CI 1.14至1.61)。
- 与GLP-1RA相比,SGLT2i用药与治疗启动1年后包茎风险增加近两倍相关。
核心结论
- 在2型糖尿病男性中,与GLP-1RA相比,SGLT2i用药与治疗启动1年后包茎风险增加近两倍相关。
- 随访8年期间风险持续升高,提示SGLT2i用药与持续较高的包茎风险相关。
研究设计与样本
- 基于人群的活性对照新用药者队列研究,模拟目标试验。
- 纳入2016至2021年丹麦所有启动SGLT2i或GLP-1RA的成年男性二甲双胍使用者。
- 采用逆概率治疗加权平衡潜在混杂因素分布。
- 共纳入32,486名SGLT2i启动者和14,793名GLP-1RA启动者,中位随访4年(最长8年)。
主要发现
- 1年包茎风险SGLT2i新用药者为0.9%,GLP-1RA新用药者为0.5%,对应1年风险比1.88(95%CI 1.43至2.47)。
- 8年随访期间包茎累积风险SGLT2i使用者达4.8%,GLP-1RA使用者达3.6%,8年风险比1.36(95%CI 1.14至1.61)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) induce glucosuria, potentially leading to infection and inflammation in the preputial microenvironment, subsequently increasing the risk of phimosis. We aimed to investigate the risks of phimosis in males with type 2 diabetes initiating SGLT2i or glucagon-like peptide 1 receptor agonists (GLP-1RA). RESEARCH DESIGN AND METHODS: In this population-based active-comparator new-user cohort study emulating a target trial, we included all adult male metformin users in Denmark initiating SGLT2i or GLP-1RA between 2016 and 2021. We used inverse probability of treatment weighting to balance the distribution of potential confounders. We estimated weighted intention-to-treat risk and risk ratios of phimosis identified from population-based medical databases. RESULTS: In this study, we included 32,486 SGLT2i initiators and 14,793 GLP-1RA initiators with a median follow-up of 4 years (maximum 8 years). The risk of phimosis was elevated among SGLT2i users. The 1-year risk of phimosis was 0.9% among new SGLT2i users and 0.5% among new GLP-1RA users, corresponding to a 1-year risk ratio of 1.88 (95% CI, 1.43 to 2.47). During 8 years of follow-up, the risk of phimosis accumulated up to 4.8% in SGLT2i users and 3.6% in GLP-1RA users, with an 8-year risk ratio of 1.36 (95% CI, 1.14 to 1.61). CONCLUSIONS: SGLT2i use was associated with a nearly twofold increased phimosis risk 1 year after treatment initiation in men with type 2 diabetes, compared with GLP-1RA use. Over 8 years of follow-up, the risk remained elevated, indicating a persistently higher risk associated with SGLT2i use.
引用
- Ljungberg C, Nørgaard M, Vandenbroucke-Grauls C, et al. Risk of Phimosis Associated With SGLT2i Versus GLP-1RA: A Danish Cohort Study. Diabetes Care. 2025. PMID: 40737110. doi:10.2337/dc25-0693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。